| http://www.w3.org/ns/prov#value | - Mean peak (Cmax) and steady state (Css) plasma concentrations at the recommended dose were 46 and 10 mcM, respectively.[10] Patients with neuroblastoma enrolled on the phase I trial appeared to have a prolonged progression free survival and improvement in symptoms such as pain compared to those with other pediatric solid tumors. [11] Based on these preliminary results suggesting a selective effect
|
